Independent register of U.S. FDA drug recalls · updated Oct 10, 2026
RxRecalls Get alerts
Class II · Moderate risk Terminated Initiated Aug 22, 2017 (9 years ago)

Ketorolac Trom 30 mg/mL Injection

Class II — Moderate risk. May cause temporary or reversible harm; serious harm unlikely.

Why it was recalled

Crystallization: Product is being recalled due to the manufacturer's recall due to the presence of visible particulate in vials that has been identified as crystalline ketorolac calcium salt.

Cause type: Failed specification

A physical or chemical test other than potency, dissolution, impurity or stability failed - pH, viscosity, appearance, tablet integrity, fill volume. A product outside its own specification may not perform as designed, even if the active ingredient is present. All failed specification recalls.

What was recalled

Ketorolac Trom 30 mg/mL Injection, packaged in a) 1 mL vials, NDC 61786-0741-01 (Orig: 00548-9021-00), Ref: 33631 and b) 10 x 1 mL vials per tray, NDC 61786-0741-08 (Orig: 00548-9021-00), Ref: 33632, Rx only, Packaged by: RemedyRepack Inc, Indiana, PA 15704; Mfg by: Amphastar, Rancho Cucamonga, CA 91730.

Affected NDCs 0548-9021-00 61786-0741-01 61786-0741-08

Compare with the code on your package — it is the most precise check available.

Drug: Ketorolac

Recalling firm
RemedyRepack Inc.
NDC code
61786-0741-01
Origin
PA, United States
Initiated by
Voluntary: Firm initiated
FDA recall number
D-1176-2017 · FDA notice

Check, then ask. Class II means harm is possible but usually temporary or reversible. Find the lot number on your package; if it matches, ask your pharmacist about a replacement. Do not simply stop a prescribed medication on your own - the gap can be riskier than the recall. This recall is now terminated, which means the firm has finished removing the affected product; anything on pharmacy shelves today should be unaffected.

Other Ketorolac recalls

See all

Other recalls by RemedyRepack Inc.

All 2017 recalls
Class II · Moderate risk

Clindamycin HCl Capsule

CGMP Deviations - products manufactured in a shared facility with Ezetimibe tablets.

Ongoing cGMP deviation RemedyRePack Inc. D-0411-2025
Class II · Moderate risk

Carvedilol 25 mg Tablet

CGMP deviations: presence of N-Nitroso Carvedilol Impurity-1 (NNC 1), above the FDA recommended acceptable intake limit.

Terminated Nitrosamine impurity RemedyRepack Inc. D-0217-2025